2026 年 10 月 23–27 日 · Madrid · 共 3194 条
65 人 · 88 条 · 1 篇摘要
当前热度 36·可比范围峰值 41（10月25日 02:00）·近 24 小时可比范围变化 –·当前参与者 56
Tarlatamab是靶向DLL3×CD3的双特异性T细胞衔接器（BiTE），2024年获美国FDA批准用于小细胞肺癌（SCLC），是当年获批的抗体新分子之一，获批依据是在经治SCLC中较标准治疗改善缓解率与无进展生存的II期数据，此后多项III期研究持续跟进[1][2][6]。这一瘤种对铂类化疗初始敏感但耐药极快、预后恶劣，PD-(L)1抑制剂与ADC带来的获益仍然有限[4]。安全性上CRS是主要顾虑，DeLLphi-300子研究显示，周期1改为6–8小时门诊监测后任意级别CRS约60%，与48小时住院监测（62%）相当，为更大规模应用提供了可行性依据[5]。
本次ESMO 2026主席专场的LBA3报告DeLLphi-305 III期结果：ES-SCLC患者经一线化疗+度伐利尤单抗诱导后，随机接受tarlatamab+度伐利尤单抗对比度伐利尤单抗单药维持治疗。Amgen于9月8日宣布研究在期中分析即达到OS终点；会上公布的数字为：OS 21.1 vs 12.7个月（HR 0.42），PFS 7.4 vs 1.9个月（HR 0.34），CRS发生率49.6%，≥3级仅0.4%。报告人为Jacob Sands，10月24日（周六）17:18，Hall 6。
相对已有认识，DeLLphi-305把tarlatamab的证据从经治后线人群[2][5]推进到一线维持阶段，并直接与PD-L1抑制剂联合，OS HR 0.42的幅度也使其成为主席专场三场报告之一。现场帖同时在谈的另一条线是与IMforte（阿替利珠单抗+鲁比克替丁维持，OS HR 0.73）的间接对照：发帖者明确表示跨试验比较不恰当，但tarlatamab组的OS获益在数值上明显更大；另有帖文提出tarlatamab可入脑而IMforte方案不能，此点属发帖者观点，会上未见相应数据，待确认。
局限在于目前仅有会议顶线数字，OS成熟度、后续治疗线、CNS疗效、生活质量与完整安全性谱均待全文披露；durvalumab单药组PFS仅1.9个月，联合组获益能否长期维持也需更长随访验证。
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org‼️ Impressive results from DeLLphi-305 (phase III) just out this afternoon #ESMO26. Tarlatamab + durvalumab vs durvalumab alone, 1L maintenance ES-SCLC. Median OS 21.1 vs 12.7 months, HR 0.42, 58% reduction in risk of death. This is great news for people affected by small cell #lungcancer. Both drugs already have EU and UK approvals on their own. The real gap: new medicines can still take 600+ days to reach patients in lower-income European countries. Practice-changing data is only half the story. https://lungcancereurope.eu/news/tarlatamab-durvalumab-dellphi-305-sclc-survival #LCSM
在#ESMO2026上，DELLPHI-305获得全场起立鼓掌。看到ED-SCLC在生存方面展现出显著优势，令人倍感欣慰。
DeLLphi-305；ES-SCLC；接近2年的mOS；强劲的PFS信号；这几乎是我在这一领域见过的最强数据。@BTOGORG #ESMO26
ESMO 2026 just started in Madrid, one of the biggest oncology congresses of the year. Schedule of the key presentations + what already came out on Day 1 : full breakdown in the article. https://x.com/i/article/2113769981779357697
#ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1 In ES-SCLC, tarlatamab + durvalumab maintenance significantly improved outcomes vs durvalumab alone following first-line chemotherapy + durvalumab: OS: 21.1 vs 12.7 months (HR 0.42) PFS: 7.4 vs 1.9 months (HR 0.34) CRS: 49.6%; grade ≥3: 0.4%. An impressive OS benefit! Atezolizumab + lurbinectedin maintenance also demonstrated an OS benefit in IMforte (HR 0.73). Although cross-trial comparisons are inappropriate, the magnitude of the OS benefit with tarlatamab appears numerically much greater.
暂无中文译文，显示英文原文。
#ESMO26 | DeLLphi-305 – Phase III | Presidential Symposium-1 In ES-SCLC, tarlatamab + durvalumab maintenance significantly improved outcomes vs durvalumab alone following first-line chemotherapy + durvalumab: OS: 21.1 vs 12.7 months (HR 0.42) PFS: 7.4 vs 1.9 months (HR 0.34) CRS: 49.6%; grade ≥3: 0.4%. An impressive OS benefit! Atezolizumab + lurbinectedin maintenance also demonstrated an OS benefit in IMforte (HR 0.73). Although cross-trial comparisons are inappropriate, the magnitude of the OS benefit with tarlatamab appears numerically much greater.